Psoriatic Arthritis

Eli Lilly will present 27 abstracts on the safety and long-term efficacy for rheumatoid arthritis and psoriasis drugs.

Another state passes legislation to increase uptake of biosimilars.

The IL-17 inhibitor reduced the number of tender and swollen joints in at least 20% of patients with PsA.

Otezla has been found to improve the signs and symptoms of psoriatic arthritis.

Clobetasol propionate lotion can be used for the treatment of moderate-to-severe plaque psoriasis.

Sixty percent of patients taking guselkumab saw improvements in PsA disease symptoms.

New drugs for psoriatic arthritis discussed during a session at the ACR/ARHP conference.

Elevated rates of fibromyalgia found in patients with rheumatic diseases, such as psoriatic arthritis.

Few prior studies have evaluated the relative effectiveness of earlier and later lines of TNF therapy in psoriatic arthritis.

Few prior studies have evaluated the relative effectiveness of earlier and later lines of TNFi therapy in psoriatic arthritis.

Inflectra is the first biosimilar monoclonal antibody approved by the FDA.

Results from clinical trials of Taltz presented at the European Academy of Dermatology and Venereology Congress.

AbbVie’s experimental compound treats moderate-to-severe chronic plaque psoriasis.

Trial shows no increased incidence of adverse events or any new safety signals with exposure to Otezla.

Data presented at the European Academy of Dermatology and Venereology (EADV) Annual Congress shows safety and efficacy of apremilast (Otezla) over three years.

Amgen’s biosimilar Amjevita approved for variety of anti-inflammatory diseases, however, ongoing litigation may prevent it from hitting the market.

Erelzi, an etanercept biosimilar, was approved for rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and polyarticular juvenile idiopathic arthritis.

Sandoz has gained FDA-approval for Erelzi, an etanercept biosimilar.

AbbVie alleges that Amgen is infringing on 61 patents with their biosimilar.

Specialty pharmacies may be able to better monitor comorbid conditions in psoriatic arthritis patients.

Treatment and cost patterns vary among psoriatic arthritis patients who switch anti-TNFα biologic therapies.

Tofacitinib citrate (Xeljanz) treats adults with active psoriatic arthritis.

Tofacitinib citrate (Xeljanz) treats adults with active psoriatic arthritis.

Remicade treats rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, plaque psoriasis, and ulcerative colitis.

Psoriatic Arthritis Impact of Disease test can be administered via a touch screen.